Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin-induced thrombocytopenia.

Gowthami M Arepally1

  • 1Division of Hematology, Duke University Medical Center, Durham, NC.

Blood
|April 19, 2017
PubMed
Summary

Heparin-induced thrombocytopenia (HIT) is an immune reaction to heparin therapy. This review covers HIT

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder.

Blood·2026
Same author

Red cell exchange removes apixaban in patients with sickle cell disease.

Transfusion·2026
Same author

The influence of nuclear antigen form on complement activation by systemic lupus erythematosus antinuclear antibody immune complexes determined by a novel immunocapture assay.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Heparin-induced thrombocytopenia immune complexes activate the inflammasome pathway in a complement-dependent manner.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder.

bioRxiv : the preprint server for biology·2025
Same author

Targeting PIEZO1-TMEM16F Coupling to Mitigate Sickle Cell Disease Complications.

American journal of hematology·2025

Area of Science:

  • Immunology
  • Hematology
  • Pharmacology

Background:

  • Heparin-induced thrombocytopenia (HIT) is an immune complication of heparin therapy.
  • It is caused by antibodies to complexes of platelet factor 4 (PF4) and heparin.
  • Pathogenic antibodies activate platelets and monocytes, leading to a hypercoagulable state and thrombosis.

Purpose of the Study:

  • To summarize current understanding of HIT.
  • To review the pathogenesis, clinical and laboratory features, and management of HIT.
  • To highlight recent scientific developments in understanding HIT immunogenicity and disease prevention.

Main Methods:

  • Review of recent scientific developments and clinical/laboratory findings.
  • Synthesis of information on HIT pathogenesis, clinical presentation, diagnosis, and management.
  • Focus on mechanisms of PF4/heparin immunogenicity and disease susceptibility.

Main Results:

  • Anti-PF4/heparin antibodies develop commonly after heparin exposure.
  • Only a subset of sensitized patients develop severe complications like thrombocytopenia and thrombosis.
  • Recent insights have clarified disease mechanisms and informed prevention strategies.

Conclusions:

  • Understanding HIT pathogenesis is crucial for diagnosis and management.
  • Recent advances have improved our knowledge of HIT immunogenicity and susceptibility.
  • Further research and clinical insights are guiding disease prevention strategies.

Related Experiment Videos